Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|December 4, 2013
New L.B. Bohle Technology Center Advances Development of Continuous Pharmaceutical Processing
Author(s)Pharmaceutical Technology Editors
Facility in Germany provides space for evaluating continuous pharmaceutical processing equipment.
Advertisement
L.B. Bohle is constructing a technology center next to its service center in Ennigerloh, Germany to provide additional space for developing, testing, and demonstrating continuous-production process equipment for the pharmaceutical industry, the company announced in a
“Our customers are relying more and more on continuous production,” said company founder Lorenz Bohle, in the press release. “Our technology center will aid in the development of new products that improve the continuous production process because we will be able to visualize entire production lines in one plant using material from wet and dry granulation.”
At the technology center, L.B. Bohle processing experts will work with specialists from the Universities of Dusseldorf and Graz and experts from Siemens to develop new steps for the permanent and interprocess measuring, monitoring, and controlling of the continuous production process. L.B. Bohle will use these developments to produce new equipment and optimize current machinery for use in the pharmaceutical industry.
Source:
L.B. Bohle
Advertisement
Related to this article
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Advertisement
Advertisement